

ASX ANNOUNCEMENT

11 March 2025

EZZ Life Science Appoints United States Manufacturing Partner

EZZ Life Science Holdings Ltd (ASX: EZZ) ("**EZZ**" or "the Company"), a genomic life science company with a mission to improve quality of life and human health, is pleased to announce that it has entered into a manufacturing agreement with GLSP Inc. Under this agreement, GLSP Inc. will serve as EZZ's US-based manufacturer, producing a range of nutrition supplements for the North American market.

This strategic agreement marks a significant milestone for EZZ as it establishes a local manufacturing presence in the United States, ensuring enhanced production efficiencies, improved supply chain logistics, and strengthened market positioning in North America.

Under the terms of the agreement, GLSP Inc. will manufacture EZZ-branded dietary supplements in compliance with the US Food and Drug Administration (FDA) regulations and ISO-certified quality standards. The agreement ensures that all products will be manufactured to the highest industry standards, meeting strict quality control measures, including third-party laboratory testing for microbiological, and heavy metal compliance.

The partnership aligns with EZZ's broader strategy to expand its global manufacturing and distribution capabilities while catering to the growing demand for high-quality, science-backed health supplements in the US market.

EZZ's Chair, Glenn Cross, commented: "This agreement represents a pivotal step in our global expansion strategy. By manufacturing in the United States, we enhance our ability to serve customers in North America with greater speed and efficiency while maintaining our commitment to premium quality and innovation. This partnership strengthens our supply chain resilience and supports our long-term vision for sustainable growth."

Key Terms of the Agreement

- **Manufacturing Partner:** GLSP Inc. will be responsible for producing EZZ's dietary supplements in compliance with FDA regulations and ISO-certified standards.
- **Production Timeline:** Manufacturing completion is expected within 6 to 10 weeks from receipt of all production requirements and initial payment.
- Intellectual Property Protection: EZZ retains full ownership of all trademarks, patents, and formulations, with strict non-disclosure obligations on GLSP Inc.
- Quality Assurance: All products will undergo third-party laboratory testing, including
 microbiological and heavy metal analysis, to ensure compliance with international safety
 standards.

The agreement also includes provisions to safeguard EZZ's intellectual property, ensuring exclusivity over formulations, branding, and proprietary product designs.





1/55-59 Parramatta Road Lidcombe NSW 2141 ACN 608 363 604

This announcement was authorised for release by the Board of EZZ Life Science Holdings Limited.

ENDS

For further information, please contact:

Investor Relations

https://www.ezzlife.com.au/investors

ir@ezzlife.com.au